MPNs | Clinical

Parsaclisib Added to Ruxolitinib Improves Spleen Size and Symptom Burden in Myelofibrosis

April 11, 2021

The addition of parsaclisib to ruxolitinib led to improvement in spleen volume reduction and symptom burden in patients with myelofibrosis who had a suboptimal response on a standard dose of ruxolitinib alone, according to results from a phase 2 study.

Givinostat Shows Promise for Long-Term Use in Patients With Polycythemia Vera

March 31, 2021

In patients with polycythemia vera, long-term use of the histone deacetylase inhibitor givinostat may be warranted after the agent demonstrated tolerable safety and good efficacy over a 4-year period in an ongoing, multicenter, open-label, single-arm study of patients with a chronic myeloproliferative neoplasm who are positive for a JAK2 V617F mutation.

FDA Issues CRL for Ropeginterferon alfa-2b-njft BLA in PV

March 15, 2021

The FDA has issued a complete response letter to PharmaEssentia Corporation for the company’s biologics license application for ropeginterferon alfa-2b-njft as a potential treatment for patients with polycythemia vera.